{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-009977","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2023-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.951407+00:00","generated_at":"2026-06-17T15:01:56.679466+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Reneo reports Q4 2022 net loss $13.6M; STRIDE study enrollment complete","bullets":["Full-year 2022 net loss $52.0M ($2.12 per share) vs $39.8M loss in 2021.","Cash, equivalents & short-term investments $101.2M as of Dec 31, 2022.","R&D expenses $37.7M in 2022, up 34% due to STRIDE and STRIDE AHEAD studies.","Pivotal STRIDE study (PMM) enrolled target 200 patients; topline results expected Q4 2023.","Plans to study mavodelpar in PMM due to nDNA defects and advance LC-FAOD program into Phase 2."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-009977","json":"https://secwatch.observer/filing/0000950170-23-009977.json","markdown":"https://secwatch.observer/filing/0000950170-23-009977.md","text":"https://secwatch.observer/filing/0000950170-23-009977.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000095017023009977/0000950170-23-009977-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000095017023009977/rphm-20230327.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T15:01:56.679466+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3aaeae6201a1261f3eb3e865b458f9286b658f07","claim":"OnKure Therapeutics, Inc. reported the fourth quarter and year ended December 31, 2022 results: net income net loss of $13.6 million, or $0.56 per share, during the fourth quarter of 2022.","evidence_excerpt":"We reported a net loss of $13.6 million, or $0.56 per share, during the fourth quarter of 2022, compared to a net loss of $10.6 million, or $0.43 per share, for the same period in 2021. For the full year 2022, we reported a net loss of $52.0 million, or $2.12 per share, compared to a net loss of $39.8 million, or $2.19 per share, for the full year 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000095017023009977/0000950170-23-009977-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Net income","value":"net loss of $13.6 million, or $0.56 per share, during the fourth quarter of 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}